PA
ALXO icon

Parallel Advisors’s ALX Oncology ALXO Stock Holding History

Parallel Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-204
Closed -$1.23K – 3398
2024
Q2 		$1.23K Hold
204
– – ﹤0.01% 2911
2024
Q1 		$2.27K Sell
204
-125
-38% -$1.76K ﹤0.01% 2790
2023
Q4 		$4.9K Hold
329
– – ﹤0.01% 2537
2023
Q3 		$1.58K Buy
+329
New +$1.78K ﹤0.01% 2884
2021
Q4 		– Sell
-86
Closed -$3.71K – 3057
2021
Q3 		$6K Buy
+86
New +$5.73K ﹤0.01% 2266

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallel Advisors's ALXO Position: Q3 2024 in Review

Parallel Advisors sold out of ALX Oncology (ALXO) in Q3 2024, closing a stake of 204 shares — an estimated $1.23K sold.

Parallel Advisors first reported a position in ALXO in Q3 2021 and held it in 5 quarters. The position peaked at $6K in Q3 2021. 92 funds tracked by Wall St. Rank hold ALXO as of Q3 2024.

  • Parallel Advisors reported no remaining ALX Oncology position as of Q3 2024 after selling out during the quarter.
  • Parallel Advisors sold 204 ALX Oncology shares in Q3 2024, an estimated $1.23K.
  • Parallel Advisors first reported a position in ALX Oncology in Q3 2021 and held it in 5 quarters.
  • Parallel Advisors's ALX Oncology position peaked at $6K in Q3 2021.
  • 92 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2024.

Based on Parallel Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.